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SUMMARY
SETTING—To assess the revised World Health Organization-recommended dose of 10–20 mg/kg 
rifampicin (RMP), we studied the steady state pharmacokinetics of RMP in South African children 
who received standard treatment for drug-susceptible tuberculosis (TB).
OBJECTIVE—To determine the formulation effect on the pharmacokinetics of RMP.
DESIGN—RMP plasma concentrations were characterised in 146 children (median age 1.4 years, 
range 0.2–10.2). The morning dose on the day of the pharmacokinetic evaluation was administered 
as one of two RMP single-drug oral suspensions.
RESULTS—While one formulation achieved 2 h concentrations in the range of those observed in 
adults (median 6.54 mg/l, interquartile range [IQR] 4.47–8.84), the other attained a median 
bioavailability of only 25% of this, with a median 2 h concentration of 1.59 mg/l (IQR 0.89–2.38).
CONCLUSION—RMP is a key drug for the treatment of TB. It is critical that the quality of RMP 
suspensions used to treat childhood TB is ensured.
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Few studies have been conducted in children to support drug dosing for tuberculosis (TB) or 
to evaluate drug formulations.1 Instead, paediatric doses have generally been extrapolated 
from those used in adults. The World Health Organization (WHO) reviewed the evidence on 
first-line anti-tuberculosis drug formulation and dosage in children and found that rifampicin 
(RMP) concentrations were low and varied widely between and within studies.2,3 Although 
sampling processes and assay methods varied across studies, and forms of dosage, methods 
of administration and dosing schedules were not consistently described, experts concluded 
that the RMP dose in children needed to be increased to achieve concentrations comparable 
to those in adults. The WHO accordingly revised its dosing guidelines in 2010, 
recommending a 50% increase in the dose of RMP, from 10 (8–12) to 15 (10–20) mg/kg.4 
We evaluated the pharmacokinetics of RMP, isoniazid (INH), pyrazinamide (PZA) and 
ethambutol (EMB) in children with TB at doses consistent with the revised WHO 
guidelines. Here we report findings regarding formulation effects on the pharmacokinetics of 
RMP.
STUDY POPULATION AND METHODS
Children aged < 12 years diagnosed with drug-susceptible TB who were receiving RMP, 
INH and PZA (with or without EMB or ethionamide) in daily doses at Red Cross Children’s 
Hospital, Tygerberg Hospital and Khayelitsha District Hospital, Cape Town, South Africa, 
were enrolled. The children were treated using fixed-dose combination (FDC) products 
available in the public health sector, with doses approximating the WHO’s 2010 guidelines.4 
Children underwent pharmacokinetic evaluation after at least 2 weeks of anti-tuberculosis 
treatment. On the day of pharmacokinetic evaluation, single-drug formulations of registered 
products were administered by the study team, as FDC products providing doses in 
accordance with the revised WHO recommendations are not yet available. A granulate 
preparation of RMP for suspension (Eremfat®, RIEMSER Arzneimittel, Germany, registered 
for use in several European countries) was reconstituted to a concentration of 100 mg/5 ml 
and administered in accurately measured doses of 10–20 mg/kg using a syringe, or via a 
nasogastric tube in very young children. Due to an interruption in the supply of Eremfat, R-
Cin® suspension (100 mg/5 ml; Aspen Pharmacare, Durban, South Africa, registered for use 
in South Africa) was used in subsequently enrolled children.
Serial 0.6 ml blood samples were drawn to determine the plasma pharmacokinetics of the 
anti-tuberculosis drugs. A pre-dose sample and samples at 2 and 4 h after the dose were 
drawn in all 146 children. An additional sample was drawn at 8 h in 86 children; in 20 
children additional samples were taken at 1, 6 and 10 h; and in 40 children an additional 
sample was drawn at 1, 6 and 8 h after the dose. The samples were centrifuged to separate 
the plasma within 0.5 h of sampling and stored immediately at −70°C until analysis.
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The study (NCT01637558) protocol was approved by the Human Research Ethics 
Committee of the Faculty of Health Sciences, University of Cape Town, Cape Town, and the 
South African Medicines Control Council, Pretoria, South Africa.
RMP plasma concentrations were determined using a liquid chromatography–mass 
spectrometry assay validated according to Federal Drug Administration (FDA) and 
European Medicines Agency (EMA) guidelines.4–6 The samples were processed with a 
protein precipitation extraction method using 20 μl plasma with 500 μl acetonitrile 
containing a stable isotope-labelled internal standard, RMP-D3. Five microliters of the 
supernatant were injected onto the high-performance liquid chromatography column. 
Chromatographic separation was achieved on a Discovery C18, 5 μm, 50 × 4.6 mm 
analytical column using acetonitrile, methanol and 0.1% formic acid in water (6:1:3, v/v/v) 
as the mobile phase, delivered at a constant flow rate of 400 μl/min. An AB Sciex API 3000 
mass spectrometer (GenTech, Arcade, NY, USA) was operated at unit resolution in the 
multiple-reaction monitoring mode, monitoring the transition of the protonated molecular 
ions at m/z 823.4 to the product ions at m/z 791.4 for RMP and the protonated molecular 
ions at m/z 826.5 to the product ions at m/z 794.4 for the internal standard. Electrospray 
ionisation was used for ion production. The assay was validated over the concentration range 
of 0.117–30 μg/ml. The combined accuracy and precision statistics of the limit of 
quantification, low, medium and high quality controls (three validation batches, n=18) were 
between 101% and 107%, and 2.7% and 3.7%, respectively.
A truncated area under the RMP concentration-time curve to 4 h after the dose (AUC0–4) 
was computed as a measure of systemic RMP exposure using the concentrations from the 
sampling times common to all children (pre-dose, 2 and 4 h) in a non-compartmental 
analysis. Concentrations below the limit of quantification of the assay (respectively 95%, 0% 
and 2% for the pre-dose, 2 h and 4 h concentrations) were imputed a value of 0.06 mg/l. 
Differences between the groups of children receiving Eremfat and R-Cin RMP suspensions 
were compared using the Mann-Whitney U-test. Quantile regression was used as a robust 
approach to adjust for the effects of age, sex, dose per kg of body weight, human 
immunodeficiency virus (HIV) status and administration by nasogastric tube when 
evaluating the effect of formulation on AUC0–4. Each of these variables was tested 
separately, and then added to the base model describing the effect of formulation on the 
AUC0–4. Covariate effects with P < 0.2 were retained in the final model. Non-compartmental 
analysis and all statistical analyses were performed using Stata 13.1 (StataCorp LP, College 
Station, TX, USA).
The RMP content of the Eremfat and R-Cin formulations was compared using product 
batches used during the study. A fresh suspension of Eremfat was prepared as described in 
the product insert. The suspension was shaken well before 200 μl was added to 40 ml 
methanol. Similarly, 200 μl of the well-shaken R-Cin suspension from a freshly opened 
bottle was added to 40 ml methanol. The two suspensions were chromatographed with a 
gradient high-performance liquid chromatography-ultraviolet assay at a flow rate of 0.4 ml/
min. Mobile phase A consisted of a mixture of 0.1% formic acid in water and acetonitrile 
(85:15, v/v), and mobile phase B consisted of 0.1% formic acid in acetonitrile. A mobile 
phase gradient was run from 100% A to 100% B over 3 min and remained at 100% B for 
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another minute before returning to 100% over 0.5 min. Five microliters were injected onto a 
Phenomenex Max-RP 3 μ 50×2 mm column (Phenomenex, Torrance, CA, USA), and RMP 
was detected at a wavelength of 334 nm. A similar method was used to evaluate the effect of 
passage through a nasogastric tube on the RMP concentrations in a RMP suspension.
RESULTS
Among the 146 children included in the analysis, 92 received Eremfat and 54 received R-
Cin formulations (Table 1). Children receiving R-Cin RMP suspension were younger 
(median 0.88 vs. 1.97 years, P < 0.001), and thus had lower body weight (median 8.37 vs. 
11.48 kg, P < 0.001). They also received slightly higher doses of RMP in mg/kg (median 
16.51 vs. 14.95). The children underwent pharmacokinetic sampling a median of 1.3 months 
(interquartile range [IQR] 1.1–1.6) after starting anti-tuberculosis treatment.
Plasma RMP concentrations by time after dose are shown in the Figure. The median 2 h 
concentration was 6.54 mg/l (IQR 4.47–8.84) in children receiving Eremfat, higher than the 
1.59 mg/l (IQR 0.89–2.38) for those receiving R-Cin (Figure). The median RMP AUC0–4 
was respectively 16.85 (IQR 11.80–23.24) and 4.19 (IQR 2.68–6.68) mg.h/l in the groups 
who received Eremfat and R-Cin RMP. When stratified by age, the RMP AUC0–4 remained 
consistently lower in children receiving R-Cin than in those who received Eremfat (Table 2, 
P < 0.001).
In univariate quantile regression, R-Cin was associated with a 12.81 mg.h/l (95% confidence 
interval [CI] −15.39 to −10.23) reduction in AUC0–4 compared to Eremfat RMP. Age, sex, 
HIV status or administration by nasogastric tube had no impact on the model describing the 
effect of formulation on AUC0–4. In the multivariate model adjusted for the effect of RMP 
dose per kg of body weight (AUC0–4 increased by 0.48 mg.h/l, 95%CI −0.03 to 0.10, for 
each 1 mg/kg increase in the dose), the strength of association slightly increased, with 
administration of R-Cin being associated with a 13.30 mg.h/l (95%CI −16.40 to −10.20) 
reduction in AUC0–4 compared to the administration of Eremfat RMP.
The RMP content of the two suspensions from the respective batches used during the study 
were equivalent, with RMP peak areas on the chromatogram for Eremfat and R-Cin 
solutions of respectively 2180 and 2047.
DISCUSSION
Under the National TB Control Programme, dispersible FDCs are used to treat the majority 
of South African children with TB. However, commercial suspensions may be useful in the 
most vulnerable of children requiring individualised care, including the very young or 
critically ill.
RMP exposures were dependent on the paediatric product used and were 76% lower among 
children who received the R-Cin suspension than in those who received Eremfat. While the 
children who received R-Cin were younger and weighed less, they received, on average, a 
higher dose of RMP per kg of body weight, and the differences in AUC0–4 between the two 
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groups remained high (79%) even when adjusted for the effect of dose per kg of body 
weight.
For adults, a 2 h target RMP concentration of 8–20 mg/l has been proposed,7 and recent 
studies suggest that even higher exposures may be more effective.8–10 Despite the 
administration of a 15 mg/kg dose, as recommended in the most recent WHO guidelines, the 
median 2 h concentration achieved was only 1.59 mg/l (IQR 0.89–2.38) for children 
receiving R-Cin. Those receiving Eremfat RMP had a median 2 h concentration of 6.54 mg/l 
(IQR 4.47–8.84), in keeping with concentrations reported in adults with TB on standard 
anti-tuberculosis treatment,11 but lower than the proposed target of 8–20 mg/l for patients on 
standard treatment.
Although RMP may be adsorbed to certain plastics, the results of the multivariate analysis 
found that administration by nasogastric tube did not exert a detectable effect on RMP 
exposures in the children. We also measured RMP concentrations in an RMP suspension 
passed through a nasogastric tube. Aliquots of suspension left to stand for 30 min at room 
temperature in three nasogastric tubes were found to have similar RMP concentrations to a 
control aliquot of the suspension (data not shown).
Several reports of substandard and counterfeit RMP-containing products have been 
published. In most instances, these reports are based on in vitro tests such as the 
concentration of the active pharmaceutical ingredient and disintegration.12–14 An analysis of 
the RMP concentrations in the two formulations studied revealed almost identical RMP 
content. This indicates that the amount of RMP in R-Cin was adequate, and that the drug 
was stable in the suspension. We therefore hypothesise that the differences observed in 
bioavailability are due to the mixture of polymorphic forms of RMP in R-Cin that was not 
favourable for absorption. Low RMP concentrations attributed to formulation effects have 
been reported in adults with TB.15,16
Production of the active pharmaceutical ingredient is complex and can lead to forms of the 
molecule with variable solubility.17 RMP exists in anhydrous polymorphic forms (Form I 
and Form II), and also in amorphous form.18 As Form II is metastable, suspension my result 
in phase transition to a more stable form with subsequent crystal growth. The water 
solubility of RMP is reported to vary eight-fold depending on the crystalline state of the 
material,19 altered particle size affects solubility,20 and altered solubility is likely to affect 
bioavailability. However, the relationship between solid-state RMP, dissolution and 
bioavailability characteristics is poorly understood. Regulatory authorities, including the 
FDA and the EMA, would generally require in vivo bioequivalence testing for a suspension 
of a drug such as RMP.21,22 Likewise, in vivo bioequivalence studies are generally required 
for suspensions under the South African Medicines Control Council (MCC) guidelines. 
Although the guidelines state that waivers based on comparative dissolution studies may be 
acceptable,23 this condition should not be applied to a Biopharmaceutics Classification 
System Class II drug such as RMP.24 The methods used to test the active pharmaceutical 
ingredient and final product, R-Cin, and the results of such tests that were used to obtain 
MCC approval, are unknown to the investigators, as both the manufacturer and the 
regulatory authority regard this information as confidential.
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Our study was not designed to compare the bioavailability of the formulations used, and the 
estimates of the effect of formulation type on the bioavailability of RMP were limited by a 
relatively small sample size for accurate adjustment for potentially confounding factors such 
as age, weight and nasogastric tube use. Nor were accurate measures of disease severity 
available for inclusion in the multivariate analysis. However, the massive impact of 
formulation on RMP exposures in these children is clear.
CONCLUSIONS
Our incidental findings reveal extremely low RMP concentrations in children as a result of 
very poor RMP bioavailability in a suspension licensed in South Africa. The findings raise 
important questions about the quality of the RMP-containing formulations available for 
children and the procedures in place to protect children from products that do not deliver 
adequate drug exposures.
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Figure. 
Plasma RMP concentrations in 146 children during the pharmacokinetic sampling interval 
for children who received Eremfat® RMP (grey diamonds) and R-Cin® RMP (black circles). 
The dotted line and solid lines track the median splines for the concentrations after doses of 
Eremfat and R-Cin, respectively, over time. RMP = rifampicin.
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Table 1
Characteristics of enrolled children, RMP dose per kg of body weight, and administration by nasogastric tube 
on the day of pharmacokinetic evaluation by RMP formulation
Formulation
Eremfat® RMP (n = 92)
median [IQR]
R-Cin® RMP (n = 54)
median [IQR] P value
Age, years 1.97 [0.94–4.37] 0.88 [0.5–2.47] < 0.001
Weight, kg 11.48 [8.27–15.45] 8.37 [5.7–13.3] < 0.001
HIV-infected, n (%)* 5 (5) 6 (11) 0.217
Female, n (%) 43 (47) 17 (31) 0.070
Dose, mg/kg 14.95 [12.20–16.68] 16.51 [14.85–18.67] 0.002
Nasogastric tube, n (%) 14 (15) 26 (48) < 0.001
*At the time of pharmacokinetic sampling, four children had not started antiretroviral treatment, one child was receiving an efavirenz-based 
regimen and the remaining children were on lopinavir/ritonavir with two nucleoside reverse transcriptase inhibitors.
RMP = rifampicin; IQR = interquartile range; HIV = human immunodeficiency virus.
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Table 2
Truncated RMP AUC (AUC0–4, mg.h/l) by age group and RMP formulation
Age group years
Eremfat® RMP
median [IQR]
R-Cin® RMP
median [IQR] P value
< 1 14.33 [8.31–18.48] [n = 26] 4.65 [3.26–6.68] [n = 31] < 0.001
1–< 2 18.49 [14.16–23.24] [n = 20] 2.53 [2.32–4.69] [n = 8] < 0.001
2–< 5 21.72 [15.90–30.15] [n = 25] 4.23 [3.17–8.56] [n = 11] < 0.001
5–< 12 15.65 [11.47–17.55] [n = 21] 4.02 [2.50–8.60] [n = 4] 0.014
RMP = rifampicin; AUC = area under the curve; IQR = interquartile range.
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